Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Michael James Burke MD

Michael James Burke MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology and Oncology - Pediatrics
Program: Oncology

Member of the Cancer Center


Publications

  • Replacement of cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide /etoposide during Consolidation/Delayed Intensification does not improve outcome for pediatric B-ALL: a report from the COG. (Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP) Haematologica 2018 Dec 13 PMID: 30545921 12/14/2018    
  • Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. (Andolina JR, Burke MJ, Hijiya N, Chaudhury S, Schultz KR, Roth ME) Biol Blood Marrow Transplant 2018 Sep 26 PMID: 30267760 09/30/2018    
  • Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia. (Becktell K, Houser K, Burke MJ) J Pediatr Hematol Oncol 2019 Jan;41(1):e38-e40 PMID: 29668549 04/19/2018    
  • Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. (Schulte RR, Madiwale MV, Flower A, Hochberg J, Burke MJ, McNeer JL, DuVall A, Bleyer A) Leuk Lymphoma 2018 Oct;59(10):2360-2368 PMID: 29431566 02/13/2018    
  • Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. (Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP) Cancer 2018 Mar 15;124(6):1150-1159 PMID: 29266189 PMCID: PMC5839964 12/22/2017    
  • Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. (Bhojwani D, Burke MJ, Horton T, Ziegler DS, Sulis ML, Schultz KR, Wayne A, Izraeli S, Chang BH) Pediatr Hematol Oncol 2017 Sep - Oct;34(6-7):355-364 PMID: 29190164 PMCID: PMC6191173 12/01/2017    
  • Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. (Burke MJ, Devidas M, Maloney K, Angiolillo A, Schore R, Dunsmore K, Larsen E, Mattano LA Jr, Salzer W, Winter SS, Carroll W, Winick NJ, Loh ML, Raetz E, Hunger SP, Bleyer A) Leuk Lymphoma 2018 07;59(7):1624-1633 PMID: 29115886 PMCID: PMC5940583 11/09/2017       2 Citations
  • Cohesin Mutations in Myeloid Malignancies. (Fisher JB, McNulty M, Burke MJ, Crispino JD, Rao S) Trends Cancer 2017 04;3(4):282-293 PMID: 28626802 PMCID: PMC5472227 06/20/2017       7 Citations
  • Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes. (Schloemer NJ, Brickler M, Hoffmann R, Pan A, Simpson P, McFadden V, Block J, Tower RL 2nd, Burke MJ) J Pediatr Hematol Oncol 2017 07;39(5):e254-e258 PMID: 28452856 PMCID: PMC5591641 04/30/2017       2 Citations
  • Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. (Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, Chen IM, Valentine M, Liu Y, Li Y, Shao Y, Easton J, Payne-Turner D, Gu Z, Tran TH, Nguyen JV, Devidas M, Dai Y, Heerema NA, Carroll AJ 3rd, Raetz EA, Borowitz MJ, Wood BL, Angiolillo AL, Burke MJ, Salzer WL, Zweidler-McKay PA, Rabin KR, Carroll WL, Zhang J, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP) Blood 2017 06 22;129(25):3352-3361 PMID: 28408464 PMCID: PMC5482101 04/15/2017       41 Citations
  • Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. (Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA Jr, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG) Nat Commun 2016 11 08;7:13331 PMID: 27824051 PMCID: PMC5105166 11/09/2016       24 Citations
  • Identification of High-risk Cryptic CRLF2 Rearrangements in B-Cell Acute Lymphoblastic Leukemia Utilizing an FGFR3/IGH Dual-Color Dual-Fusion DNA Probe Set. (Robin AJ, Peterson JF, Grignon JW Jr, Gheorghe G, Burke MJ, vanTuinen P) J Pediatr Hematol Oncol 2017 05;39(4):e207-e210 PMID: 27820126 11/08/2016    
  • Oncolytic Seneca Valley Virus: past perspectives and future directions. (Burke MJ) Oncolytic Virother 2016;5:81-9 PMID: 27660749 PMCID: PMC5019429 09/24/2016    
  • Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. (Burke MJ, Rheingold SR) Leuk Lymphoma 2017 03;58(3):540-551 PMID: 27546298 08/23/2016       2 Citations
  • Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. (Sun W, Orgel E, Malvar J, Sposto R, Wilkes JJ, Gardner R, Tolbert VP, Smith A, Hur M, Hoffman J, Rheingold SR, Burke MJ, Wayne AS) Pediatr Blood Cancer 2016 11;63(11):1943-8 PMID: 27437864 07/21/2016       4 Citations
  • A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. (Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, Heerema NA, Wood BL, Borowitz MJ, Burke MJ, Asselin BL, Devidas M, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE) J Pediatr Hematol Oncol 2016 08;38(6):409-17 PMID: 27299599 PMCID: PMC4955695 06/15/2016       2 Citations
  • Minimal Residual Disease in NPM1-Mutated AML. (Burke MJ) N Engl J Med 2016 Feb 04;374(5):481-2 PMID: 26789634 01/21/2016       1 Citations
  • Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. (Lu BY, Thanawala SU, Zochowski KC, Burke MJ, Carroll WL, Bhatla T) Leuk Lymphoma 2016 08;57(8):1938-41 PMID: 26726842 01/05/2016       4 Citations
  • Emerging immunotherapy in pediatric lymphoma. (Erker C, Harker-Murray P, Burke MJ) Future Oncol 2016 Jan;12(2):257-70 PMID: 26616565 12/01/2015    
  • Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. (Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GMT, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL) Biol Blood Marrow Transplant 2015 Dec;21(12):2154-2159 PMID: 26327632 PMCID: PMC4654112 09/04/2015       7 Citations
  • Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. (Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM) Pediatr Blood Cancer 2015 May;62(5):743-50 PMID: 25307519 PMCID: PMC4376652 10/14/2014       14 Citations
  • How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. (Burke MJ) Future Oncol 2014 Dec;10(16):2615-27 PMID: 24983955 07/02/2014       14 Citations
  • A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. (Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS) Am J Hematol 2014 Sep;89(9):889-95 PMID: 24891274 PMCID: PMC4134715 06/04/2014       40 Citations
  • Epigenetic modifications in pediatric acute lymphoblastic leukemia. (Burke MJ, Bhatla T) Front Pediatr 2014;2:42 PMID: 24860797 PMCID: PMC4030177 05/27/2014    
  • A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD). (Gossai N, Verneris MR, Karras NA, Gorman MF, Patel NJ, Burke MJ) Bone Marrow Transplant 2014 Mar;49(3):440-2 PMID: 24317126 12/10/2013       5 Citations
  • Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation. (Burke MJ, Gossai N, Cao Q, Macmillan ML, Warlick E, Verneris MR) Bone Marrow Transplant 2014 Feb;49(2):174-8 PMID: 24185590 11/05/2013       11 Citations
  • Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population. (Pratt JA, Stricherz MK, Verghese PS, Burke MJ) Pediatr Blood Cancer 2014 Feb;61(2):366-8 PMID: 24038944 09/17/2013    
  • How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. (Burke MJ, Burns L, Linden MA, Lindgren B, Verneris MR, Weisdorf D, Ustun C) Am J Hematol 2013 Sep;88(9):826-7 PMID: 23737091 PMCID: PMC3772519 06/06/2013       1 Citations
  • Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. (Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR) Biol Blood Marrow Transplant 2013 Jul;19(7):1021-5 PMID: 23567175 PMCID: PMC3712759 04/10/2013       15 Citations
  • Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. (Smith AR, Christiansen EC, Wagner JE, Cao Q, MacMillan ML, Stefanski HE, Trotz BA, Burke MJ, Verneris MR) Pediatr Blood Cancer 2013 Apr;60(4):705-10 PMID: 23152304 PMCID: PMC3668778 11/16/2012       13 Citations
  • Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. (Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, MacMillan ML, Stefanski HS, Weisdorf DJ, Verneris MR) Biol Blood Marrow Transplant 2013 Jan;19(1):138-42 PMID: 22960388 PMCID: PMC3530019 09/11/2012       14 Citations
  • Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. (Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, Carroll WL) Blood 2012 May 31;119(22):5201-10 PMID: 22496163 PMCID: PMC3369610 04/13/2012       73 Citations
  • Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. (Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ) Biol Blood Marrow Transplant 2012 Jun;18(6):963-8 PMID: 22430088 PMCID: PMC3631589 03/21/2012       22 Citations
  • Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. (Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C, Weisdorf D, Miller JS, Wagner JE, Verneris MR) Biol Blood Marrow Transplant 2012 Jun;18(6):930-6 PMID: 22108570 PMCID: PMC4378716 11/24/2011       18 Citations
  • Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians. (Burke MJ, Lindgen B, Verneris MR) Pediatr Blood Cancer 2012 Jun;58(6):840-5 PMID: 21796765 07/29/2011       4 Citations
  • Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. (Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D) Blood 2011 May 12;117(19):5261-3 PMID: 21403127 PMCID: PMC3109547 03/16/2011       6 Citations
  • Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. (Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ) Bone Marrow Transplant 2011 Jul;46(7):950-5 PMID: 20856210 09/22/2010       12 Citations
  • Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. (Burke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, Weisdorf D, Wagner JE, Verneris MR) Biol Blood Marrow Transplant 2011 Jun;17(6):831-40 PMID: 20831896 PMCID: PMC3412271 09/14/2010       24 Citations
  • Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. (Smith AR, Gulbahce E, Burke MJ, Cao Q, Macmillan ML, Tolar J, Orchard PJ, Blazar BR, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2011 Mar;46(3):368-71 PMID: 20548337 PMCID: PMC3556271 06/16/2010       4 Citations
  • Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. (Verneris MR, Burke MJ) Curr Hematol Malig Rep 2010 Jul;5(3):157-62 PMID: 20446122 05/07/2010       2 Citations
  • Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. (Verneris MR, Eapen M, Duerst R, Carpenter PA, Burke MJ, Afanasyev BV, Cowan MJ, He W, Krance R, Li CK, Tan PL, Wagner JE, Davies SM) Biol Blood Marrow Transplant 2010 Sep;16(9):1237-44 PMID: 20302960 PMCID: PMC2904410 03/23/2010       25 Citations
  • Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. (Beck JC, Burke MJ, Tolar J) Pediatr Blood Cancer 2010 Mar;54(3):490-1 PMID: 19908296 11/13/2009       13 Citations
  • Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). (Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR) Pediatr Blood Cancer 2009 Dec 15;53(7):1289-94 PMID: 19731318 09/05/2009       19 Citations
  • Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. (Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE) Blood 2009 Nov 05;114(19):4293-9 PMID: 19706886 PMCID: PMC2774557 08/27/2009       209 Citations
  • The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. (Burke MJ, Willert J, Desai S, Kadota R) Pediatr Blood Cancer 2009 Dec;53(6):992-5 PMID: 19621426 07/22/2009       8 Citations
  • Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. (Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Aug;44(3):169-74 PMID: 19204709 02/11/2009       11 Citations
  • Treatment of a CNS relapse while on therapy for Burkitt lymphoma. (Burke MJ, Dayton V) Pediatr Blood Cancer 2009 Feb;52(2):290-2 PMID: 18937319 10/22/2008       2 Citations
  • Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. (Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Jan;43(2):107-13 PMID: 18776928 09/09/2008       40 Citations
  • Cardiac risks of imatinib in chronic myelogenous leukemia (CML) patients who receive allogeneic hematopoietic cell transplantation (Allo-HCT). (Burke MJ, Gursahaney A, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Michael VR) J Clin Oncol 2008 May 20;26(15_suppl):7039 PMID: 27949600 05/20/2008    
  • Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. (Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M) Pediatr Blood Cancer 2007 Aug;49(2):196-8 PMID: 17417796 04/10/2007       23 Citations
  • Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. (Burke MJ, Cohn SL) Pediatr Blood Cancer 2008 Mar;50(3):679-80 PMID: 16900484 08/11/2006       17 Citations
  • Last update: 12/26/2018
    jenkins-FCD Prod-299 9ef562391eceb2b8f95265c767fbba1ce5a52fd6